瑞联新材(688550.SH)：医药业务目前主要以创新药中间体为主

Core Viewpoint - The company focuses on innovative pharmaceutical intermediates in its medical business, with growth expected in the first half of 2025 due to adjustments in customer procurement demands and increased volume of certain innovative pharmaceutical intermediates [1] Summary by Categories Company Overview - The company, 瑞联新材 (688550.SH), is primarily engaged in the production of innovative pharmaceutical intermediates [1] Business Growth Factors - Growth in the pharmaceutical segment for the first half of 2025 is attributed to adjustments in customer procurement needs and the further ramp-up of certain innovative pharmaceutical intermediates [1]